AFFY  Affymax Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Current Price

-0.008 (-8.000%)

Book Price

Overvalued by 351.37%
Financial Institution

Company Metrics

  • 2.25 P/E
  • 131.22 P/S
  • 1.07 P/B
  • 0.082 EPS
  • 0.05 / 0% Dividend
  • 42,824.00 Avg. Vol.
  • 6.7M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Telestone Technologies Corp.
Affymax, Inc.'s Pain Becomes Amgen Inc.'s Gain
iStockAnalyst (press release) - Feb 25, 2013
(By Mani) Affymax, Inc. (NASDAQ: AFFY) announced a national voluntary recall of all lots of Omontys after reports of serious hypersensitivity reactions including anaphylaxis.
Affymax stock plunges 85 percent on drug recall - Reuters
Affymax Shares Plunge on Drug's Recall - Wall Street Journal
Affymax, Inc. (OTCMKTS:AFFY) Slumps a Little Further
HotStocked - Sep 20, 2013
52AFFY_chart.png In yesterday's session the stock of Affymax, Inc. (OTCMKTS:AFFY, AFFY message board) traded in above-average volume once again, but the price action sent the ticker 2% in the red.
Hedge Funds Are Selling Affymax, Inc. (AFFY) - Northwest Biotherapeutics, Inc ...
Insider Monkey (blog) - Apr 8, 2013
When looking at the hedgies we track, OrbiMed Advisors, managed by Samuel Isaly, holds the most valuable position in Affymax, Inc. (NASDAQ:AFFY). OrbiMed Advisors has a $48.9 million position in the stock, comprising 1.5% of its 13F portfolio.
Here is What Hedge Funds Think About Affymax, Inc. (AFFY)
Insider Monkey (blog) - Jun 10, 2013
Is Affymax, Inc. (NASDAQ:AFFY) a first-rate investment now? The smart money is taking a pessimistic view. The number of long hedge fund positions were cut by 4 recently.
Affymax, Inc. (OTCMKTS:AFFY) Rising in The Midst of a “Review War”
HotStocked - Aug 30, 2013
If you have followed our articles on Affymax, Inc. (OTCMKTS:AFFY, AFFY message board) you would know that they are having trouble with their drug OMONTYS, that was voluntarily withdrawn from the market after several fatalities of patients treated with it.
Lawsuit on Behalf of Affymax, Inc. (AFFY) Investors Over Alleged Misleading ...
GlobeNewswire (press release) - Mar 4, 2013
SAN DIEGO, March 4, 2013 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of purchasers of Affymax, Inc. (AFFY) common stock during the period between December 8, 2011 and February 22, 2013 ...